Optimization of the preparation of 99mTc-labeled Hynic-derivatized Annexin V for human use

Nuclear Medicine and Biology

Volumn 30, Issue 7, 2003, Pages 771-778

  Verbeke, Kristin ^a,c   Kieffer, Davy ^a   Vanderheyden, Jean Luc ^b   Reutelingsperger, Chris ^d   Steinmetz, Neil ^b   Green, Allan ^b   Verbruggen, Alfons ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Theseus Imaging Corporation   (United States)

^c FUND FOR SCIENTIFIC RESEARCH   (Belgium)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Annexin V; Apoptosis; Hynic; Technetium 99m

Indexed keywords

HYNEXIN TC 99M; ISOTOPE; LIGAND; LIPOCORTIN 5; PROTEIN; REDUCING AGENT; TIN CHLORIDE; UNCLASSIFIED DRUG; WATER; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M HYNIC ANNEXIN V;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DRUG SCREENING; DRUG SYNTHESIS; FAST PROTEIN LIQUID CHROMATOGRAPHY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; THIN LAYER CHROMATOGRAPHY; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; CHROMATOGRAPHY; COMPARATIVE STUDY; DRUG DESIGN; DRUG STABILITY; EVALUATION; METABOLIC CLEARANCE RATE; METHODOLOGY; QUALITY CONTROL; SYNTHESIS; TISSUE DISTRIBUTION; VALIDATION STUDY;

ANIMALS; ANNEXIN A5; CHROMATOGRAPHY; DRUG DESIGN; DRUG STABILITY; HUMANS; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; ORGANOTECHNETIUM COMPOUNDS; QUALITY CONTROL; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 0141448717     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00056-8     Document Type: Article

References (20)

1. Abrams M.J., Juweid M., tenKate C.I., Schwartz D.A., Hauser M.M., Gaul F.E., Fucello A.J., Rubin R.H., Strauss H.W., Fischman A.J. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 31:1990;2022-2028.
2. Blankenberg F.G., Katsikis P.D., Tait J.F., Davis R.E., Naumovski L., Ohtsuki K., Kopiwoda S., Abrams M.J., Darkes M., Robbins R.C., Maecker H.T., Strauss H.W. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA. 95:1998;6349-6354.
3. 99mTc-Annexin V. J Nucl Med. 40:1999;184-191.
4. Decristoforo C., Mather S.J. Technetium-99m somatostatin analogues effect of labelling methods and peptide sequence . Eur J Nucl Med. 26:1999;869-876.
5. 99mTc . Bioconjugate Chem. 8:1997;146-154.
6. Ercan M.T. Rapid determination of hydrolyzed-reduced technetium-99m in particulate radiopharmaceuticals. Appl Radiat Isot. 43:1992;1175-1177.
7. 99mTc-N,N′-bis-(mercaptoacetamide)ethylenediamine. Effect of renal tubular inhibitors. Int J Nucl Med Biol. 9:1982;79-82.
8. King T.P., Zhao S.W., Lam T. Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry. 25:1986;5774-5779.
9. 99mTc labeling of hydrazino nicotinamide modified proteins . J Labelled Compds Radiopharm. 35:1994;1-2.
10. 99mTc using aminocarboxylates as coligands. Bioconjugate Chem. 7:1996;63-71.
11. 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands. Bioconjugate Chem. 9:1998;583-595.
12. Ohtsuki K., Akashi K., Aoka Y., Blankenberg F.G., Kopiwoda S., Tait J.F., Strauss H.W. Technetium-99m HYNIC-Annexin V a potential radiopharmaceutical for the in-vivo detection of apoptosis . Eur J Nucl Med. 26:1999;1251-1258.
13. Ono M., Arano Y., Uehara T., Fuijoka Y., Ogawa K., Namba S., Mukai T., Nakayama M., Saji M. Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins. Bioconjugate Chem. 10:1999;386-394.
14. 99mTc-labeled polypeptides wih low in vivo protein binding. Nucl Med Biol. 28:2001;215-224.
15. Rennen H.J.J.M., Boerman O.C., Koenders E.B., Oyen W.J.G., Corstens F.H.M. Labeling proteins with Tc-99m via hydrazinonicotinamide (HYNIC) optimization of the conjugation reaction . Nucl Med Biol. 27:2000;599-604.
16. Robers M., Rensink I.J.A.M., Hack C.E., Aarden L.A., Reutelingsperger C.P.M., Glatz J.F.C., Hermens W.T.h. A new principle for rapid immunoassay of proteins based on in situ precipitate-enhanced ellipsometry. Biophys J. 76:1999;2769-2776.
17. Steffen M.G., Oosterwijk E., Kranenborg M.H.G.C., Manders J.M.B., Debruyne F.M.J., Corstens F.H.M., Boerman O.C. In vivo and in vitro characterization of three, 99mTc-labeled monoclonal antibody G250 preparations. J Nucl Med. 40:1999;829-836.
18. 99mTc. Bioconjugate Chem. 11:2000;918-925.
19. Ultee M.E., Bridger G.J., Abrams M.J., Longley C.B., Burton C.A., Larsen S.K., Henson G.W., Padmanabhan S., Gaul F.E., Schwartz D.A. Tumor imaging with technetium-99m labeled hydrazinonicotinamide-Fab' conjugates. J Nucl Med. 38:1997;133-138.
20. m-MAG3-HSA as possible blood pool agents. Nucl Med Commun. 16:1995;942-957.